(+)-catechin multiple interactions ISO RGD:732384 6480464 [Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of IGFBP5 mRNA CTD PMID:24763279 (1->4)-beta-D-glucan multiple interactions ISO RGD:10776 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of IGFBP5 mRNA CTD PMID:36331819 (R,R,R)-alpha-tocopherol multiple interactions EXP 6480464 [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA CTD PMID:23859036 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane decreases expression ISO RGD:10776 6480464 2 more ... CTD PMID:11509743 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane affects expression EXP 6480464 2 more ... CTD PMID:19414516 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane multiple interactions EXP 6480464 2 more ... CTD PMID:19414516 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane multiple interactions ISO RGD:10776 6480464 [Estradiol co-treated with 2 more ... CTD PMID:11509743 1,10-phenanthroline decreases degradation EXP 6480464 1, 10-phenanthroline results in decreased degradation of IGFBP5 protein CTD PMID:8894652 1,2-dichloroethane increases expression ISO RGD:10776 6480464 ethylene dichloride results in increased expression of IGFBP5 mRNA CTD PMID:28960355 1,2-dimethylhydrazine increases expression ISO RGD:10776 6480464 1, 2-Dimethylhydrazine results in increased expression of IGFBP5 mRNA CTD PMID:22206623 1,2-dimethylhydrazine multiple interactions ISO RGD:10776 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of IGFBP5 mRNA CTD PMID:22206623 1-naphthyl isothiocyanate decreases expression EXP 6480464 1-Naphthylisothiocyanate results in decreased expression of IGFBP5 mRNA CTD PMID:30723492 14-Deoxy-11,12-didehydroandrographolide decreases expression ISO RGD:732384 6480464 14-deoxy-11, 12-didehydroandrographolide results in decreased expression of IGFBP5 mRNA CTD PMID:22101062 17alpha-ethynylestradiol increases expression ISO RGD:10776 6480464 Ethinyl Estradiol results in increased expression of IGFBP5 mRNA CTD PMID:17942748 17alpha-ethynylestradiol decreases expression ISO RGD:732384 6480464 Ethinyl Estradiol results in decreased expression of IGFBP5 mRNA CTD PMID:18936297 17alpha-ethynylestradiol affects expression EXP 6480464 Ethinyl Estradiol affects the expression of IGFBP5 mRNA CTD PMID:17557909 17alpha-ethynylestradiol multiple interactions ISO RGD:10776 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of IGFBP5 mRNA CTD PMID:17942748 17beta-estradiol multiple interactions ISO RGD:732384 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of IGFBP5 mRNA more ... CTD PMID:19619570 more ... 17beta-estradiol decreases expression ISO RGD:732384 6480464 Estradiol results in decreased expression of IGFBP5 mRNA CTD PMID:15159206 more ... 17beta-estradiol affects expression ISO RGD:732384 6480464 Estradiol affects the expression of IGFBP5 mRNA CTD PMID:14699072 , PMID:21826169 17beta-estradiol decreases expression ISO RGD:10776 6480464 Estradiol results in decreased expression of IGFBP5 mRNA CTD PMID:11509743 17beta-estradiol multiple interactions ISO RGD:10776 6480464 [Estradiol co-treated with 2 more ... CTD PMID:11509743 17beta-estradiol increases expression ISO RGD:732384 6480464 Estradiol results in increased expression of IGFBP5 mRNA CTD PMID:17555868 , PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:732384 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of IGFBP5 mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of IGFBP5 mRNA CTD PMID:33387578 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:732384 6480464 Tetrachlorodibenzodioxin affects the expression of IGFBP5 mRNA CTD PMID:36370075 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of IGFBP5 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:10776 6480464 Tetrachlorodibenzodioxin results in increased expression of IGFBP5 mRNA CTD PMID:26139165 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:10776 6480464 Tetrachlorodibenzodioxin affects the expression of IGFBP5 mRNA CTD PMID:17555868 , PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:732384 6480464 Tetrachlorodibenzodioxin results in increased expression of IGFBP5 mRNA CTD PMID:17555868 , PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:10776 6480464 Tetrachlorodibenzodioxin results in decreased expression of IGFBP5 mRNA CTD PMID:16054899 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:10776 6480464 [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA] more ... CTD PMID:16054899 , PMID:17942748 2,4,6-trinitrobenzenesulfonic acid multiple interactions ISO RGD:10776 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA] CTD PMID:18200517 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:10776 6480464 Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA CTD PMID:17982090 , PMID:18200517 2-amino-2-deoxy-D-glucopyranose multiple interactions EXP 6480464 Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] CTD PMID:17109745 2-amino-2-deoxy-D-glucopyranose increases expression EXP 6480464 Glucosamine results in increased expression of IGFBP5 mRNA CTD PMID:17109745 2-methylcholine affects expression ISO RGD:732384 6480464 beta-methylcholine affects the expression of IGFBP5 mRNA CTD PMID:21179406 3',5'-cyclic AMP multiple interactions EXP 6480464 2 more ... CTD PMID:19414516 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:23196670 3,3',5,5'-tetrabromobisphenol A decreases expression ISO RGD:10776 6480464 tetrabromobisphenol A results in decreased expression of IGFBP5 mRNA CTD PMID:25172293 3,3',5,5'-tetrabromobisphenol A decreases expression ISO RGD:732384 6480464 tetrabromobisphenol A results in decreased expression of IGFBP5 mRNA CTD PMID:33476716 3,4-methylenedioxymethamphetamine increases expression ISO RGD:10776 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of IGFBP5 mRNA CTD PMID:20188158 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:10776 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA more ... CTD PMID:16054899 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:732384 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of IGFBP5 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol decreases expression ISO RGD:732384 6480464 bis(4-hydroxyphenyl)sulfone results in decreased expression of IGFBP5 mRNA CTD PMID:33476716 4,4'-sulfonyldiphenol increases expression ISO RGD:10776 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of IGFBP5 mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide decreases expression ISO RGD:732384 6480464 Fenretinide results in decreased expression of IGFBP5 mRNA CTD PMID:16671099 4-hydroxyphenyl retinamide decreases expression ISO RGD:10776 6480464 Fenretinide results in decreased expression of IGFBP5 mRNA CTD PMID:28973697 4-nitrophenol decreases expression ISO RGD:10776 6480464 4-nitrophenol results in decreased expression of IGFBP5 mRNA CTD PMID:34673133 4-vinylcyclohexene dioxide affects expression ISO RGD:10776 6480464 4-vinyl-1-cyclohexene dioxide affects the expression of IGFBP5 mRNA CTD PMID:20829426 5-aza-2'-deoxycytidine multiple interactions ISO RGD:732384 6480464 Decitabine inhibits the reaction [monomethylarsonous acid results in decreased expression of IGFBP5 mRNA] CTD PMID:16507463 5-fluorouracil decreases expression ISO RGD:732384 6480464 Fluorouracil results in decreased expression of IGFBP5 mRNA CTD PMID:16557594 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of IGFBP5 mRNA CTD PMID:24780913 8-Br-cAMP increases expression ISO RGD:732384 6480464 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP5 mRNA CTD PMID:20147733 , PMID:22079614 acrylamide decreases expression ISO RGD:732384 6480464 Acrylamide results in decreased expression of IGFBP5 mRNA CTD PMID:32763439 aldehydo-D-glucosamine increases expression EXP 6480464 Glucosamine results in increased expression of IGFBP5 mRNA CTD PMID:17109745 aldehydo-D-glucosamine multiple interactions EXP 6480464 Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] CTD PMID:17109745 all-trans-retinoic acid increases expression ISO RGD:10776 6480464 Tretinoin results in increased expression of IGFBP5 mRNA CTD PMID:16604517 all-trans-retinoic acid decreases expression ISO RGD:732384 6480464 Tretinoin results in decreased expression of IGFBP5 mRNA CTD PMID:21934132 , PMID:23724009 all-trans-retinoic acid multiple interactions ISO RGD:732384 6480464 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of IGFBP5 mRNA CTD PMID:16443354 aluminium trifluoride increases expression ISO RGD:732384 6480464 aluminum fluoride results in increased expression of IGFBP5 mRNA, aluminum fluoride results in increased expression of IGFBP5 protein CTD PMID:11996908 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of IGFBP5 mRNA CTD PMID:16483693 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of IGFBP5 mRNA CTD PMID:30779732 amphotericin B decreases expression ISO RGD:732384 6480464 Amphotericin B results in decreased expression of IGFBP5 mRNA CTD PMID:20849824 antirheumatic drug increases expression ISO RGD:732384 6480464 Antirheumatic Agents results in increased expression of IGFBP5 mRNA CTD PMID:24449571 aristolochic acid A decreases expression ISO RGD:732384 6480464 aristolochic acid I results in decreased expression of IGFBP5 mRNA CTD PMID:33212167 arsane multiple interactions ISO RGD:732384 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of IGFBP5 mRNA CTD PMID:32525701 arsenic atom multiple interactions ISO RGD:732384 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of IGFBP5 mRNA CTD PMID:32525701 arsenite(3-) multiple interactions ISO RGD:732384 6480464 arsenite inhibits the reaction [Fulvestrant results in increased expression of IGFBP5 mRNA] CTD PMID:31646340 arsenite(3-) decreases expression ISO RGD:732384 6480464 arsenite results in decreased expression of IGFBP5 mRNA CTD PMID:31646340 arsenous acid increases expression ISO RGD:732384 6480464 Arsenic Trioxide results in increased expression of IGFBP5 protein CTD PMID:27430728 arsenous acid multiple interactions ISO RGD:732384 6480464 [Arsenic Trioxide co-treated with Curcumin] results in increased expression of IGFBP5 protein CTD PMID:27430728 atrazine increases expression ISO RGD:732384 6480464 Atrazine results in increased expression of IGFBP5 mRNA CTD PMID:22378314 benzamidine decreases degradation EXP 6480464 benzamidine results in decreased degradation of IGFBP5 protein CTD PMID:8894652 benzo[a]pyrene decreases expression ISO RGD:10776 6480464 Benzo(a)pyrene results in decreased expression of IGFBP5 mRNA CTD PMID:22610609 benzo[a]pyrene increases methylation ISO RGD:732384 6480464 Benzo(a)pyrene results in increased methylation of IGFBP5 5' UTR, Benzo(a)pyrene results in increased methylation of IGFBP5 exon CTD PMID:27901495 benzylpenicillin decreases expression ISO RGD:732384 6480464 Penicillin G results in decreased expression of IGFBP5 mRNA CTD PMID:24737281 beta-carotene multiple interactions EXP 6480464 [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA CTD PMID:23859036 beta-D-glucosamine multiple interactions EXP 6480464 Glucosamine inhibits the reaction [IL1B results in increased expression of IGFBP5 mRNA] CTD PMID:17109745 beta-D-glucosamine increases expression EXP 6480464 Glucosamine results in increased expression of IGFBP5 mRNA CTD PMID:17109745 bicalutamide increases expression EXP 6480464 bicalutamide results in increased expression of IGFBP5 mRNA CTD PMID:10604720 bis(2-chloroethyl) sulfide decreases expression ISO RGD:10776 6480464 Mustard Gas results in decreased expression of IGFBP5 mRNA CTD PMID:15674843 bisphenol A affects expression ISO RGD:732384 6480464 bisphenol A affects the expression of IGFBP5 mRNA CTD PMID:21826169 bisphenol A increases expression ISO RGD:10776 6480464 bisphenol A results in increased expression of IGFBP5 mRNA CTD PMID:30951980 , PMID:32156529 bisphenol A decreases expression ISO RGD:732384 6480464 bisphenol A results in decreased expression of IGFBP5 mRNA CTD PMID:29275510 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of IGFBP5 mRNA CTD PMID:25181051 more ... Bisphenol B increases expression ISO RGD:732384 6480464 bisphenol B results in increased expression of IGFBP5 protein CTD PMID:34186270 bisphenol F decreases expression ISO RGD:732384 6480464 bisphenol F results in decreased expression of IGFBP5 mRNA CTD PMID:33476716 bisphenol F increases expression ISO RGD:732384 6480464 bisphenol F results in increased expression of IGFBP5 protein CTD PMID:34186270 bisphenol F increases expression ISO RGD:10776 6480464 bisphenol F results in increased expression of IGFBP5 mRNA CTD PMID:30951980 C60 fullerene decreases expression EXP 6480464 fullerene C60 results in decreased expression of IGFBP5 mRNA CTD PMID:19167457 cadmium atom decreases expression ISO RGD:732384 6480464 Cadmium results in decreased expression of IGFBP5 mRNA CTD PMID:31646340 cadmium atom multiple interactions ISO RGD:732384 6480464 Cadmium inhibits the reaction [Fulvestrant results in increased expression of IGFBP5 mRNA] CTD PMID:31646340 cadmium dichloride increases expression EXP 6480464 Cadmium Chloride results in increased expression of IGFBP5 mRNA CTD PMID:15454312 calcitriol multiple interactions ISO RGD:732384 6480464 IGFBP5 protein inhibits the reaction [Calcitriol results in increased expression of COL1A1 protein] CTD PMID:17595320 calcium atom affects expression EXP 6480464 Calcium affects the expression of IGFBP5 mRNA CTD PMID:15913539 calcium atom decreases degradation EXP 6480464 Calcium results in decreased degradation of IGFBP5 protein CTD PMID:8894652 calcium(0) decreases degradation EXP 6480464 Calcium results in decreased degradation of IGFBP5 protein CTD PMID:8894652 calcium(0) affects expression EXP 6480464 Calcium affects the expression of IGFBP5 mRNA CTD PMID:15913539 carbamazepine affects expression ISO RGD:732384 6480464 Carbamazepine affects the expression of IGFBP5 mRNA CTD PMID:25979313 carbon nanotube affects expression ISO RGD:10776 6480464 Nanotubes, Carbon analog affects the expression of IGFBP5 mRNA CTD PMID:25620056 carbon nanotube decreases expression ISO RGD:10776 6480464 Nanotubes more ... CTD PMID:25554681 CGP 52608 multiple interactions ISO RGD:732384 6480464 CGP 52608 promotes the reaction [RORA protein binds to IGFBP5 gene] CTD PMID:28238834 chloroprene increases expression EXP 6480464 Chloroprene results in increased expression of IGFBP5 mRNA CTD PMID:23125180 chlorpyrifos decreases expression EXP 6480464 Chlorpyrifos results in decreased expression of IGFBP5 mRNA CTD PMID:18668222 cisplatin decreases expression ISO RGD:10776 6480464 Cisplatin results in decreased expression of IGFBP5 mRNA CTD PMID:21151649 cisplatin decreases expression ISO RGD:732384 6480464 Cisplatin results in decreased expression of IGFBP5 mRNA CTD PMID:20849824 cisplatin affects response to substance ISO RGD:732384 6480464 IGFBP5 protein affects the susceptibility to Cisplatin CTD PMID:16217747 clobetasol decreases expression ISO RGD:10776 6480464 Clobetasol results in decreased expression of IGFBP5 mRNA CTD PMID:27462272 copper atom increases expression EXP 6480464 Copper results in increased expression of IGFBP5 mRNA CTD PMID:30556269 copper(0) increases expression EXP 6480464 Copper results in increased expression of IGFBP5 mRNA CTD PMID:30556269 corticosterone decreases expression EXP 6480464 Corticosterone results in decreased expression of IGFBP5 mRNA CTD PMID:15755911 cortisol decreases expression ISO RGD:732384 6480464 Hydrocortisone results in decreased expression of IGFBP5 mRNA CTD PMID:21267416 coumestrol multiple interactions ISO RGD:732384 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 coumestrol decreases expression ISO RGD:732384 6480464 Coumestrol results in decreased expression of IGFBP5 mRNA CTD PMID:19167446 crocidolite asbestos decreases expression ISO RGD:732384 6480464 Asbestos, Crocidolite results in decreased expression of IGFBP5 mRNA CTD PMID:29523930 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of IGFBP5 mRNA CTD PMID:26577399 curcumin multiple interactions ISO RGD:10776 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IGFBP5 mRNA] CTD PMID:18200517 curcumin multiple interactions ISO RGD:732384 6480464 [arsenic trioxide co-treated with Curcumin] results in increased expression of IGFBP5 protein CTD PMID:27430728 cyclophosphamide decreases expression ISO RGD:10776 6480464 Cyclophosphamide results in decreased expression of IGFBP5 mRNA CTD PMID:15331540 cyclophosphamide decreases expression ISO RGD:732384 6480464 Cyclophosphamide results in decreased expression of IGFBP5 mRNA CTD PMID:20849824 cyclosporin A increases expression EXP 6480464 Cyclosporine results in increased expression of IGFBP5 mRNA CTD PMID:21865292 cytarabine decreases expression ISO RGD:732384 6480464 Cytarabine results in decreased expression of IGFBP5 mRNA CTD PMID:21198554 dexamethasone multiple interactions ISO RGD:10776 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of IGFBP5 mRNA more ... CTD PMID:16054899 dexamethasone multiple interactions ISO RGD:732384 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of IGFBP5 mRNA CTD PMID:28628672 dexamethasone increases expression ISO RGD:732384 6480464 Dexamethasone results in increased expression of IGFBP5 mRNA CTD PMID:25047013 dexamethasone multiple interactions EXP 6480464 Testosterone inhibits the reaction [Dexamethasone results in decreased expression of IGFBP5 mRNA] CTD PMID:20032058 dexamethasone decreases expression EXP 6480464 Dexamethasone results in decreased expression of IGFBP5 mRNA CTD PMID:20032058 diarsenic trioxide increases expression ISO RGD:732384 6480464 Arsenic Trioxide results in increased expression of IGFBP5 protein CTD PMID:27430728 diarsenic trioxide multiple interactions ISO RGD:732384 6480464 [Arsenic Trioxide co-treated with Curcumin] results in increased expression of IGFBP5 protein CTD PMID:27430728 dibenz[a,h]anthracene decreases expression ISO RGD:10776 6480464 1 more ... CTD PMID:26377693 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of IGFBP5 mRNA CTD PMID:21266533 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of IGFBP5 mRNA CTD PMID:15829613 dimethylarsinous acid decreases expression ISO RGD:732384 6480464 dimethylarsinous acid results in decreased expression of IGFBP5 mRNA CTD PMID:16507463 dioxygen multiple interactions EXP 6480464 [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of IGFBP5 mRNA CTD PMID:33729688 disodium selenite multiple interactions EXP 6480464 [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA CTD PMID:23859036 diuron decreases expression EXP 6480464 Diuron results in decreased expression of IGFBP5 mRNA CTD PMID:25152437 dorsomorphin multiple interactions ISO RGD:732384 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:10776 6480464 Doxorubicin results in decreased expression of IGFBP5 protein CTD PMID:30517846 doxorubicin increases expression ISO RGD:732384 6480464 Doxorubicin results in increased expression of IGFBP5 mRNA CTD PMID:29803840 doxorubicin decreases expression ISO RGD:732384 6480464 Doxorubicin results in decreased expression of IGFBP5 mRNA CTD PMID:30031762 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of IGFBP5 mRNA CTD PMID:29391264 Enterolactone multiple interactions ISO RGD:732384 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IGFBP5 mRNA CTD PMID:19167446 entinostat multiple interactions ISO RGD:732384 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA CTD PMID:27188386 entinostat decreases expression ISO RGD:732384 6480464 entinostat results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 estriol decreases expression ISO RGD:732384 6480464 Estriol results in decreased expression of IGFBP5 mRNA CTD PMID:15159206 ethanol multiple interactions ISO RGD:732384 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of IGFBP5 mRNA CTD PMID:23378141 ethanol increases expression ISO RGD:10776 6480464 Ethanol results in increased expression of IGFBP5 mRNA CTD PMID:30319688 ethanol affects splicing ISO RGD:10776 6480464 Ethanol affects the splicing of IGFBP5 mRNA CTD PMID:30319688 ethanol increases expression ISO RGD:732384 6480464 Ethanol results in increased expression of IGFBP5 mRNA CTD PMID:23378141 ethylenediaminetetraacetic acid decreases degradation EXP 6480464 Edetic Acid results in decreased degradation of IGFBP5 protein CTD PMID:8894652 flavonoids decreases expression EXP 6480464 Flavonoids results in decreased expression of IGFBP5 mRNA CTD PMID:18035473 fluvastatin multiple interactions ISO RGD:732384 6480464 [zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA CTD PMID:16996129 folic acid affects expression ISO RGD:732384 6480464 Folic Acid affects the expression of IGFBP5 mRNA CTD PMID:17320366 folic acid multiple interactions ISO RGD:10776 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of IGFBP5 mRNA CTD PMID:22206623 folic acid multiple interactions ISO RGD:732384 6480464 [Ethanol co-treated with Folic Acid] results in increased expression of IGFBP5 mRNA CTD PMID:23378141 formaldehyde increases expression ISO RGD:732384 6480464 Formaldehyde results in increased expression of IGFBP5 mRNA CTD PMID:28937961 fulvestrant increases expression ISO RGD:732384 6480464 Fulvestrant results in increased expression of IGFBP5 mRNA CTD PMID:31646340 fulvestrant multiple interactions ISO RGD:732384 6480464 arsenite inhibits the reaction [Fulvestrant results in increased expression of IGFBP5 mRNA] more ... CTD PMID:31646340 genistein decreases expression EXP 6480464 Genistein results in decreased expression of IGFBP5 mRNA CTD PMID:22504913 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of IGFBP5 mRNA CTD PMID:22061828 , PMID:33387578 gentamycin decreases expression ISO RGD:732384 6480464 Gentamicins results in decreased expression of IGFBP5 mRNA CTD PMID:20849824 hydrazines decreases expression ISO RGD:10776 6480464 Hydrazines results in decreased expression of IGFBP5 mRNA CTD PMID:21647536 hydrogen peroxide increases expression ISO RGD:732384 6480464 Hydrogen Peroxide results in increased expression of IGFBP5 mRNA CTD PMID:12414654 , PMID:32949572 Indeno[1,2,3-cd]pyrene decreases expression ISO RGD:10776 6480464 indeno(1 more ... CTD PMID:26377693 indometacin multiple interactions ISO RGD:732384 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of IGFBP5 mRNA CTD PMID:28628672 irinotecan increases expression EXP 6480464 Irinotecan results in increased expression of IGFBP5 mRNA CTD PMID:20097248 isoflavones affects expression ISO RGD:732384 6480464 Isoflavones affects the expression of IGFBP5 mRNA CTD PMID:16365062 isotretinoin increases expression ISO RGD:732384 6480464 Isotretinoin results in increased expression of IGFBP5 mRNA CTD PMID:20436886 L-ascorbic acid multiple interactions ISO RGD:732384 6480464 [Tretinoin co-treated with Ascorbic Acid] results in decreased expression of IGFBP5 mRNA CTD PMID:16443354 L-ascorbic acid multiple interactions EXP 6480464 [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA CTD PMID:23859036 lead diacetate decreases expression EXP 6480464 lead acetate results in decreased expression of IGFBP5 mRNA CTD PMID:11578147 linuron decreases expression EXP 6480464 Linuron results in decreased expression of IGFBP5 mRNA CTD PMID:12730624 lipopolysaccharide multiple interactions ISO RGD:732384 6480464 [S-(1 more ... CTD PMID:35811015 manganese(II) chloride increases expression EXP 6480464 manganese chloride results in increased expression of IGFBP5 mRNA CTD PMID:28801915 medroxyprogesterone acetate decreases expression ISO RGD:732384 6480464 Medroxyprogesterone Acetate results in decreased expression of IGFBP5 mRNA CTD PMID:20843944 menadione increases expression ISO RGD:732384 6480464 Vitamin K 3 results in increased expression of IGFBP5 mRNA CTD PMID:12414654 mercury dibromide decreases expression ISO RGD:732384 6480464 mercuric bromide results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 metacetamol decreases expression ISO RGD:10776 6480464 3-hydroxyacetanilide results in decreased expression of IGFBP5 mRNA CTD PMID:18544908 methamphetamine multiple interactions EXP 6480464 IGFBP5 mutant form inhibits the reaction [Methamphetamine results in increased activity of CASP3 protein], IGFBP5 mutant form inhibits the reaction [Methamphetamine results in increased activity of PARP1 protein] CTD PMID:25127757 methamphetamine increases expression EXP 6480464 Methamphetamine results in increased expression of IGFBP5 mRNA, Methamphetamine results in increased expression of IGFBP5 protein CTD PMID:25127757 methotrexate increases expression EXP 6480464 Methotrexate results in increased expression of IGFBP5 mRNA CTD PMID:15120968 methoxychlor multiple interactions ISO RGD:10776 6480464 [Estradiol co-treated with Methoxychlor metabolite] results in decreased expression of IGFBP5 mRNA CTD PMID:11509743 methoxychlor decreases expression EXP 6480464 Methoxychlor results in decreased expression of IGFBP5 mRNA CTD PMID:23303685 methoxychlor decreases expression ISO RGD:10776 6480464 Methoxychlor metabolite results in decreased expression of IGFBP5 mRNA CTD PMID:11509743 Methylazoxymethanol acetate increases expression EXP 6480464 Methylazoxymethanol Acetate results in increased expression of IGFBP5 mRNA CTD PMID:28349193 methylmercury chloride decreases expression ISO RGD:732384 6480464 methylmercuric chloride results in decreased expression of IGFBP5 mRNA CTD PMID:28001369 mifepristone decreases expression ISO RGD:732384 6480464 Mifepristone results in decreased expression of IGFBP5 mRNA CTD PMID:17584828 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of IGFBP5 mRNA CTD PMID:28801915 N-nitrosodiethylamine increases expression ISO RGD:732384 6480464 Diethylnitrosamine results in increased expression of IGFBP5 mRNA CTD PMID:21527772 N-nitrosodiethylamine decreases expression ISO RGD:10776 6480464 Diethylnitrosamine results in decreased expression of IGFBP5 mRNA CTD PMID:24535843 N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of IGFBP5 mRNA CTD PMID:17032414 nitrofen decreases expression EXP 6480464 nitrofen results in decreased expression of IGFBP5 mRNA, nitrofen results in decreased expression of IGFBP5 protein CTD PMID:19844724 Nonylphenol decreases expression ISO RGD:732384 6480464 nonylphenol results in decreased expression of IGFBP5 mRNA CTD PMID:15159206 oxaliplatin decreases expression EXP 6480464 oxaliplatin results in decreased expression of IGFBP5 mRNA CTD PMID:25729387 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of IGFBP5 mRNA CTD PMID:25729387 ozone multiple interactions ISO RGD:10776 6480464 [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of IGFBP5 mRNA CTD PMID:34911549 p-chloromercuribenzoic acid decreases expression ISO RGD:732384 6480464 p-Chloromercuribenzoic Acid results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions ISO RGD:732384 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA CTD PMID:27188386 p-menthan-3-ol decreases expression ISO RGD:732384 6480464 Menthol results in decreased expression of IGFBP5 mRNA CTD PMID:26760959 paracetamol decreases expression ISO RGD:10776 6480464 Acetaminophen results in decreased expression of IGFBP5 mRNA CTD PMID:18544908 paraquat increases expression EXP 6480464 Paraquat results in increased expression of IGFBP5 mRNA CTD PMID:18198484 pentane-2,3-dione decreases expression EXP 6480464 2, 3-pentanedione results in decreased expression of IGFBP5 mRNA CTD PMID:25710175 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:10776 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of IGFBP5 mRNA CTD PMID:36331819 phenformin decreases expression EXP 6480464 Phenformin results in decreased expression of IGFBP5 mRNA CTD PMID:31324951 phenobarbital affects expression ISO RGD:10776 6480464 Phenobarbital affects the expression of IGFBP5 mRNA CTD PMID:23091169 phenylephrine decreases expression EXP 6480464 Phenylephrine results in decreased expression of IGFBP5 mRNA CTD PMID:18158353 phenylmethanesulfonyl fluoride decreases degradation EXP 6480464 Phenylmethylsulfonyl Fluoride results in decreased degradation of IGFBP5 protein CTD PMID:8894652 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:732384 6480464 [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of IGFBP5 mRNA CTD PMID:16979875 pirinixic acid multiple interactions ISO RGD:10776 6480464 PPARA protein promotes the reaction [pirinixic acid results in decreased expression of IGFBP5 mRNA] CTD PMID:20059764 pirinixic acid decreases expression ISO RGD:10776 6480464 pirinixic acid results in decreased expression of IGFBP5 mRNA CTD PMID:20059764 , PMID:23811191 pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of IGFBP5 mRNA CTD PMID:12832660 potassium dichromate increases expression ISO RGD:10776 6480464 Potassium Dichromate results in increased expression of IGFBP5 mRNA CTD PMID:23608068 progesterone multiple interactions ISO RGD:732384 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of IGFBP5 mRNA CTD PMID:20660070 progesterone decreases expression ISO RGD:732384 6480464 Progesterone results in decreased expression of IGFBP5 mRNA CTD PMID:18070364 , PMID:20864642 propiconazole decreases expression ISO RGD:10776 6480464 propiconazole results in decreased expression of IGFBP5 mRNA CTD PMID:21278054 resveratrol decreases expression EXP 6480464 resveratrol results in decreased expression of IGFBP5 mRNA CTD PMID:19228061 resveratrol multiple interactions ISO RGD:732384 6480464 [Coumestrol co-treated with resveratrol] results in decreased expression of IGFBP5 mRNA CTD PMID:19167446 resveratrol decreases expression ISO RGD:732384 6480464 resveratrol results in decreased expression of IGFBP5 mRNA CTD PMID:15280659 rimonabant multiple interactions ISO RGD:10776 6480464 Rimonabant inhibits the reaction [Dietary Fats results in increased expression of IGFBP5 mRNA] CTD PMID:19030233 rimonabant affects expression ISO RGD:10776 6480464 Rimonabant affects the expression of IGFBP5 mRNA CTD PMID:19030233 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of IGFBP5 mRNA CTD PMID:27979718 , PMID:28374803 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:732384 6480464 [S-(1 more ... CTD PMID:35811015 S-(1,2-dichlorovinyl)-L-cysteine decreases expression ISO RGD:732384 6480464 S-(1, 2-dichlorovinyl)cysteine results in decreased expression of IGFBP5 mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:732384 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide decreases expression ISO RGD:732384 6480464 Silicon Dioxide analog results in decreased expression of IGFBP5 mRNA CTD PMID:25895662 silver atom decreases expression ISO RGD:10776 6480464 Silver results in decreased expression of IGFBP5 mRNA CTD PMID:27131904 silver(0) decreases expression ISO RGD:10776 6480464 Silver results in decreased expression of IGFBP5 mRNA CTD PMID:27131904 sirolimus decreases expression EXP 6480464 Sirolimus results in decreased expression of IGFBP5 mRNA CTD PMID:21865292 sodium arsenate multiple interactions ISO RGD:732384 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of IGFBP5 mRNA CTD PMID:32525701 sodium arsenite decreases expression ISO RGD:732384 6480464 sodium arsenite results in decreased expression of IGFBP5 mRNA CTD PMID:16507463 more ... sodium arsenite decreases expression ISO RGD:10776 6480464 sodium arsenite results in decreased expression of IGFBP5 mRNA CTD PMID:17451858 sodium arsenite increases expression ISO RGD:10776 6480464 sodium arsenite results in increased expression of IGFBP5 mRNA CTD PMID:17077188 sodium arsenite affects expression ISO RGD:10776 6480464 sodium arsenite affects the expression of IGFBP5 mRNA CTD PMID:16507464 sodium arsenite increases methylation ISO RGD:732384 6480464 sodium arsenite results in increased methylation of IGFBP5 gene CTD PMID:24570342 Soman increases expression EXP 6480464 Soman results in increased expression of IGFBP5 mRNA CTD PMID:19281266 succimer multiple interactions ISO RGD:10776 6480464 [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of IGFBP5 mRNA CTD PMID:26378955 sunitinib decreases expression ISO RGD:732384 6480464 Sunitinib results in decreased expression of IGFBP5 mRNA CTD PMID:31533062 tacrolimus hydrate increases expression EXP 6480464 Tacrolimus results in increased expression of IGFBP5 mRNA CTD PMID:21865292 tamoxifen affects expression ISO RGD:732384 6480464 Tamoxifen affects the expression of IGFBP5 mRNA CTD PMID:14699072 tamoxifen increases response to substance ISO RGD:732384 6480464 IGFBP5 protein results in increased susceptibility to Tamoxifen CTD PMID:20354179 temozolomide increases expression ISO RGD:732384 6480464 Temozolomide results in increased expression of IGFBP5 mRNA CTD PMID:31758290 tert-butyl hydroperoxide increases expression ISO RGD:732384 6480464 tert-Butylhydroperoxide results in increased expression of IGFBP5 mRNA CTD PMID:12414654 testosterone multiple interactions EXP 6480464 Testosterone inhibits the reaction [Dexamethasone results in decreased expression of IGFBP5 mRNA] CTD PMID:20032058 tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of IGFBP5 mRNA CTD PMID:17032414 tetraphene decreases expression ISO RGD:10776 6480464 benz(a)anthracene results in decreased expression of IGFBP5 mRNA CTD PMID:26377693 thapsigargin increases expression ISO RGD:732384 6480464 Thapsigargin results in increased expression of IGFBP5 mRNA CTD PMID:22378314 thapsigargin decreases expression ISO RGD:732384 6480464 Thapsigargin results in decreased expression of IGFBP5 mRNA CTD PMID:29453283 theophylline decreases expression ISO RGD:732384 6480464 Theophylline results in decreased expression of IGFBP5 mRNA CTD PMID:16083514 thimerosal decreases expression ISO RGD:732384 6480464 Thimerosal results in decreased expression of IGFBP5 mRNA CTD PMID:27188386 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of IGFBP5 mRNA CTD PMID:34492290 Thiorphan affects expression ISO RGD:732384 6480464 Thiorphan affects the expression of IGFBP5 protein CTD PMID:16405511 titanium dioxide affects expression ISO RGD:10776 6480464 titanium dioxide affects the expression of IGFBP5 mRNA CTD PMID:23557971 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of IGFBP5 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of IGFBP5 mRNA CTD PMID:25729387 trichloroethene increases methylation EXP 6480464 Trichloroethylene results in increased methylation of IGFBP5 gene CTD PMID:27618143 trichostatin A increases expression ISO RGD:732384 6480464 trichostatin A results in increased expression of IGFBP5 mRNA CTD PMID:24935251 trichostatin A multiple interactions ISO RGD:732384 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGFBP5 mRNA CTD PMID:27188386 trichostatin A decreases expression ISO RGD:732384 6480464 trichostatin A results in decreased expression of IGFBP5 mRNA CTD PMID:26272509 triclosan increases expression ISO RGD:732384 6480464 Triclosan results in increased expression of IGFBP5 mRNA CTD PMID:30510588 trimellitic anhydride decreases expression ISO RGD:10776 6480464 trimellitic anhydride results in decreased expression of IGFBP5 mRNA CTD PMID:19042947 triptonide decreases expression ISO RGD:10776 6480464 triptonide results in decreased expression of IGFBP5 mRNA CTD PMID:33045310 troglitazone increases expression ISO RGD:732384 6480464 troglitazone results in increased expression of IGFBP5 mRNA CTD PMID:19140230 troglitazone decreases expression ISO RGD:10776 6480464 troglitazone results in decreased expression of IGFBP5 mRNA CTD PMID:28973697 tunicamycin increases expression ISO RGD:732384 6480464 Tunicamycin results in increased expression of IGFBP5 mRNA CTD PMID:22378314 valproic acid decreases methylation ISO RGD:732384 6480464 Valproic Acid results in decreased methylation of IGFBP5 gene CTD PMID:29154799 valproic acid decreases expression ISO RGD:732384 6480464 Valproic Acid results in decreased expression of IGFBP5 mRNA CTD PMID:28001369 valproic acid affects expression ISO RGD:732384 6480464 Valproic Acid affects the expression of IGFBP5 mRNA CTD PMID:25979313 valproic acid increases expression ISO RGD:732384 6480464 Valproic Acid results in increased expression of IGFBP5 mRNA CTD PMID:24935251 vanadium atom increases expression ISO RGD:732384 6480464 Vanadium results in increased expression of IGFBP5 mRNA CTD PMID:19000753 vanadium(0) increases expression ISO RGD:732384 6480464 Vanadium results in increased expression of IGFBP5 mRNA CTD PMID:19000753 vancomycin increases expression ISO RGD:10776 6480464 Vancomycin results in increased expression of IGFBP5 mRNA CTD PMID:18930951 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of IGFBP5 mRNA CTD PMID:18042343 , PMID:30207508 vorinostat decreases expression ISO RGD:732384 6480464 vorinostat results in decreased expression of IGFBP5 mRNA CTD PMID:27188386 zinc atom multiple interactions ISO RGD:732384 6480464 [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of IGFBP5 mRNA CTD PMID:16979875 zinc atom multiple interactions EXP 6480464 [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA CTD PMID:23859036 zinc atom decreases expression EXP 6480464 Zinc deficiency results in decreased expression of IGFBP5 mRNA CTD PMID:20128680 zinc atom decreases degradation EXP 6480464 Zinc results in decreased degradation of IGFBP5 protein CTD PMID:8894652 zinc(0) multiple interactions ISO RGD:732384 6480464 [Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of IGFBP5 mRNA CTD PMID:16979875 zinc(0) decreases degradation EXP 6480464 Zinc results in decreased degradation of IGFBP5 protein CTD PMID:8894652 zinc(0) decreases expression EXP 6480464 Zinc deficiency results in decreased expression of IGFBP5 mRNA CTD PMID:20128680 zinc(0) multiple interactions EXP 6480464 [alpha-Tocopherol co-treated with beta Carotene co-treated with Ascorbic Acid co-treated with Zinc co-treated with Sodium Selenite] results in decreased expression of IGFBP5 mRNA CTD PMID:23859036 zoledronic acid multiple interactions ISO RGD:732384 6480464 [zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA CTD PMID:16996129